Medpace Holdings, Inc. (NASDAQ:MEDP) Stock Holdings Trimmed by Jackson Creek Investment Advisors LLC

Jackson Creek Investment Advisors LLC lessened its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 1.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 4,674 shares of the company’s stock after selling 92 shares during the period. Medpace comprises 0.5% of Jackson Creek Investment Advisors LLC’s portfolio, making the stock its 16th largest position. Jackson Creek Investment Advisors LLC’s holdings in Medpace were worth $1,433,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Contravisory Investment Management Inc. bought a new position in Medpace in the 4th quarter worth about $26,000. RiverPark Advisors LLC bought a new stake in Medpace during the 4th quarter valued at $26,000. GAMMA Investing LLC acquired a new position in Medpace during the 4th quarter worth $30,000. McGlone Suttner Wealth Management Inc. acquired a new position in shares of Medpace in the 4th quarter worth approximately $33,000. Finally, FinTrust Capital Advisors LLC bought a new stake in shares of Medpace in the 3rd quarter worth approximately $30,000. Institutional investors and hedge funds own 77.98% of the company’s stock.

Insider Activity at Medpace

In other Medpace news, CEO August J. Troendle sold 100,000 shares of Medpace stock in a transaction on Wednesday, March 6th. The shares were sold at an average price of $412.98, for a total transaction of $41,298,000.00. Following the completion of the sale, the chief executive officer now owns 4,833,019 shares of the company’s stock, valued at approximately $1,995,940,186.62. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Medpace news, Director Ashley M. Keating sold 250 shares of the business’s stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $409.87, for a total transaction of $102,467.50. Following the completion of the transaction, the director now owns 250 shares of the company’s stock, valued at approximately $102,467.50. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO August J. Troendle sold 100,000 shares of the stock in a transaction that occurred on Wednesday, March 6th. The shares were sold at an average price of $412.98, for a total value of $41,298,000.00. Following the sale, the chief executive officer now owns 4,833,019 shares of the company’s stock, valued at approximately $1,995,940,186.62. The disclosure for this sale can be found here. Over the last three months, insiders have sold 189,340 shares of company stock valued at $76,651,647. Corporate insiders own 20.30% of the company’s stock.

Medpace Stock Down 3.0 %

Shares of MEDP traded down $11.86 during mid-day trading on Tuesday, reaching $388.35. The company’s stock had a trading volume of 224,805 shares, compared to its average volume of 250,405. Medpace Holdings, Inc. has a 1 year low of $197.39 and a 1 year high of $421.00. The company has a market cap of $12.03 billion, a price-to-earnings ratio of 40.57, a price-to-earnings-growth ratio of 1.97 and a beta of 1.38. The business has a fifty day moving average of $398.00 and a 200 day moving average of $327.40.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Monday, April 22nd. The company reported $3.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.45 by $0.75. Medpace had a return on equity of 59.74% and a net margin of 15.92%. The firm had revenue of $511.00 million during the quarter, compared to the consensus estimate of $512.39 million. During the same period in the prior year, the business earned $2.27 EPS. The business’s revenue for the quarter was up 17.7% on a year-over-year basis. On average, analysts predict that Medpace Holdings, Inc. will post 11.23 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on MEDP. Guggenheim raised their target price on shares of Medpace from $453.00 to $464.00 and gave the stock a “buy” rating in a report on Wednesday, April 24th. UBS Group upgraded Medpace from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $282.00 to $452.00 in a report on Thursday, February 15th. Deutsche Bank Aktiengesellschaft assumed coverage on Medpace in a report on Monday, March 18th. They set a “hold” rating and a $395.00 target price for the company. StockNews.com upgraded Medpace from a “hold” rating to a “buy” rating in a research report on Tuesday, April 23rd. Finally, Robert W. Baird boosted their price objective on Medpace from $446.00 to $454.00 and gave the stock an “outperform” rating in a report on Wednesday, April 24th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $443.00.

Medpace Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.